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Meyerson Phenomenon as a Component of Melanoma 
in situ
 
Meyerson phenomenon (MP) is characterized by a 
symmetrical area of erythema and scales encircling a 
central lesion, which is most commonly a banal me-
lanocytic nevus. Herein, we describe an unusual case 
with MP representing an eczematized response to a 
melanoma in situ and review the literature covering 
this entity.
A 56-year-old man presented with a 6-month his-
tory of a pruritic, pigmented lesion on the trunk. The 
patient had no other significant medical history and 
no notable family history of similar lesions. Physical 
examination revealed an irregular, hyperpigmented 
plaque, 1 cm in diameter, with a surrounding halo 
of erythematous, scaly areas on the right abdominal 
region (Figure 1, a). On dermatoscopical examina-
tion, an irregular, broadened pigment network, radial 
streaming, and a focal blue-white veil, encircled by 
a homogenous, erythematous zone was observed 
(Figure 1, b). Based on clinical and dermatoscopical 
findings, a presumptive diagnosis of MP occurring on 
an early melanoma was made and the lesion was ex-
cised with a 5 mm safety margin. 
Histopathological examination of the excised 
material revealed a central intraepidermal atypical, 
confluent melanocytic proliferation with angular, hy-
perkeratotic, and irregular nuclei and a prominent 
fixation artifact around the cells (Figure 1, c). Human 
melanoma black (HMB-45) immunostaining high-
lighted the confluence of the neoplastic melanocytic 
proliferation. Lymphohistiocytic infiltration with mel-
anophages was also identified in the upper dermis. 
An interesting feature was the presence of subacute 
spongiotic dermatitis around the melanocytic le-
sions (i.e. parakeratosis, serum/crusting, spongiosis, 
lymphocyte exocytosis, and acanthosis). Immunohis-
tochemical staining with the Langerhans cell marker, 
CD1a, revealed an increased cell population in the per-
ilesional, erythematous halo (Figure 1, d). A diagnosis 
of MP existing on melanoma in situ was established 
with clinical and histopathological findings. No recur-
rence of the eczematized components or melanocytic 
lesions was identified despite 1-year follow-up.
Also called halo dermatitis and halo eczema, 
MP presents as an eczematized, perilesional plaque 
around various lesions, mainly of banal melanocytic 
nevi (1). Occurrence of halo dermatitis around a mela-
nocytic nevus was first described by Meyerson in 1971. 
Other cutaneous disorders with MP include those of 
dysplastic nevus, melanoma, seborrheic keratosis, 
stucco keratosis, nevus sebaceous, dermatofibroma, 
vascular malformations, nevus flammeus, mollus-
cum contagiosum, basal cell carcinoma, squamous 
cell carcinoma, and keloid formation (2-7). History 
of atopy and atopic dermatitis is observed in a sub-
set of patients, which was absent in our case. Rarely, 
patients with Behçet’s disease, severe sunburn, and 
cessation of interferon therapy have also been as-
sociated with this entity. MP is described to be more 
frequent in young males and has a tendency to oc-
cur in summer. As far as we are aware, there are only 
Figure 1. a) Hyperpigmented, irregular plaque with sur-
rounding erythematous halo. b) Dermatoscopical examina-
tion revealing broadened pigment network, radial stream-
ing, and focal blue-white veil, encircled by a homogenous, 
erythematous zone. c) Intraepidermal atypical, confluent 
melanocytic proliferation with angular, hyperkeratotic, and 
irregular nuclei and a prominent fixation artifact around 
the cells (hematoxylin and eosin ×100). d) Immunostaining 
for Langerhans cells revealed an increased cell population 
in the perilesional, erythematous halo (CD1a stain, ×40).
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two cases of melanoma with features of MP in the lit-
erature. Rodin et al. presented a case report showing 
features of MP around a melanoma in situ arising on a 
dysplastic nevus (8). By way of comparison, a pre-ex-
isting precursor dysplastic nevus was not identified in 
our case. Dermatoscopic features including scar-like 
depigmentation and negative pigment network also 
differed from our case which featured a broadened 
pigment network, radial streaming, and blue-white 
veil. The other case report was of a 50-year-old man, 
presenting with an atypical melanocytic lesion sev-
eral years in duration showing an erythematous halo 
(9). Histopathological examination was consistent 
with a Clark level 2 superficial spreading melanoma, 
which was cured with excision with no recurrence 
despite long-term follow-up. As far as we are aware, 
our case report is the first to describe de novo mela-
noma in situ without dermal invasion or a precursor 
dysplastic nevus. 
The etiopathology of MP is unclear; however it is 
considered to be immune-mediated. Up-regulation 
of intercellular adhesion molecule-1 on keratinocytes 
and dermal endothelial cell surfaces has been shown, 
suggesting the involvement of adhesion molecules 
in pathogenesis (10). We hypothesize that increased 
Langerhans cell population, as observed in our case, 
results in a delayed immune response reminiscent of 
an eczematous process in MP.
Excision of the central lesion has been reported to 
precipitate the resolution of dermatitis, as in our case, 
in which recurrence of the erythematous, scaly erup-
tion was not observed after removal of the central le-
sion despite a 1-year follow-up period. Some authors 
recommend pre-treatment of the lesion with topical 
corticosteroids to suppress the eczematous process 
in the adjacent skin. Coexistence of MP around a me-
lanocytic nevus (Meyerson nevus) with halo nevus 
and progression of Meyerson nevus to halo nevus has 
also been reported.
We suggest that melanoma may occur as a com-
ponent of MP, and careful dermatoscopic examina-
tion is essential to differentiate between pigmented 
lesions with a perilesional erythematous halo.
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